1uui: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1uui.gif|left|200px]]
{{Seed}}
[[Image:1uui.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1uui|  PDB=1uui  |  SCENE=  }}  
{{STRUCTURE_1uui|  PDB=1uui  |  SCENE=  }}  


'''NMR STRUCTURE OF A SYNTHETIC SMALL MOLECULE, RBT158, BOUND TO HIV-1 TAR RNA'''
===NMR STRUCTURE OF A SYNTHETIC SMALL MOLECULE, RBT158, BOUND TO HIV-1 TAR RNA===




==Overview==
<!--
The targeting of RNA for the design of novel anti-viral compounds has until now proceeded largely without incorporating direct input from structure-based design methodology, partly because of lack of structural data, and complications arising from substrate flexibility. We propose a paradigm to explain the physical mechanism for ligand-induced refolding of trans-activation response element (TAR RNA) from human immunodeficiency virus 1 (HIV-1). Based upon Poisson-Boltzmann analysis of the TAR structure, as bound by a peptide derived from the transcriptional activator protein, Tat, our hypothesis shows that two specific electrostatic interactions are necessary to stabilise the conformation. This result contradicts the belief that a single argininamide residue is responsible for stabilising the TAR fold, as well as the conventional wisdom that electrostatic interactions with RNA are non-specific or dominated by phosphates. We test this hypothesis by using NMR and computational methods to model the interaction of a series of novel inhibitors of the in vitro RNA-binding activities for a peptide derived from Tat. A subset of inhibitors, including the bis-guanidine compound rbt203 and its analogues, induce a conformation in TAR similar to that brought about by the protein. Comparison of the interactions of two of these ligands with the RNA and structure-activity relationships observed within the compound series, confirm the importance of the two specific electrostatic interactions in the stabilisation of the Tat-bound RNA conformation. This work illustrates how the use of medicinal chemistry and structural analysis can provide a rational basis for prediction of ligand-induced conformational change, a necessary step towards the application of structure-based methods in the design of novel RNA or protein-binding drugs.
The line below this paragraph, {{ABSTRACT_PUBMED_14757049}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 14757049 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_14757049}}


==About this Structure==
==About this Structure==
1UUI is a [[Single protein]] structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1UUI OCA].  
1UUI is a [[Single protein]] structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1UUI OCA].  


==Reference==
==Reference==
Line 37: Line 41:
[[Category: Rna bulge]]
[[Category: Rna bulge]]
[[Category: Tar rna]]
[[Category: Tar rna]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 11:42:41 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 02:58:55 2008''